More Access and Evidence Articles

Access and Evidence

A burning desire to make a difference for patients

Andrew Stone, (Apr 19, 2020)

Annexus Health, eyeforpharma’s 2020 Health Start-up winner is on a mission for patients
Access and Evidence

From reactive to predictive: Concerto’s new compositions

Andrew Stone, (Apr 10, 2020)

Artificial Intelligence has only just begun to unlock high value innovation. The latest predictive tools will break new ground, says Concerto HealthAI’s Jeff Elton
Access and Evidence

Evolving HTA frameworks to accelerate innovation

Andrew Stone, (Mar 14, 2020)

Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janssen’s Clare Hague
Access and Evidence

Can we afford to pay for future cures?

Ulrich Neumann, (Jan 24, 2020)

Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging
Access and Evidence

Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.
Access and Evidence

Advancing RWE together with academia

Katie Osborne, (Jan 2, 2020)

Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust
Access and Evidence

Prescription drug pricing: The times they are a changin’

Ulrich Neumann, (Nov 25, 2019)

The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value
Access and Evidence

Putting a price on life: Is the answer outside pharma?

Nicola Davies, (Nov 4, 2019)

Gene replacement and cell-based therapies are here to cure, but are we ready for them? The current difficulty pricing groundbreaking healthcare advancements suggests maybe not.
Access and Evidence

Putting The I in Pills

Izzy Gladstone, (Jun 27, 2019)

Individualised medicine has so far failed to live up to the hype but innovations in the field are on the cusp of disrupting the way pharma and healthcare develop and provide treatments.
Access and Evidence

Embracing Early Access

Katie Osborne, (Jan 22, 2019)

Compassionate use programs offer hope to patients who have ran out of options. But the benefits must be weighed against the risks.